BridgeMD
Prevention study for Ovarian Hyper Stimulation Syndrome (OHSS)
Official title Ovarian Hyperstimulation Syndrome Prevention
ClinicalTrials.gov ID: NCT06739759
What this study is testing
What is Antagonist protocol for IVF?
Antagonist protocol for IVF is an investigational medicine, being studied as a potential treatment for ovarian hyper stimulation syndrome (ohss).
Also referred to as Antagonist.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Ovarian hyperstimulation is a very hazardous complication of ICSI
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 42, women only
You may be able to join if
- Women with PCOS coming for ICSI
You likely can't join if
- Women who donnot have PCOS
The study team makes the final eligibility decision.
Where it's taking place
- Giza, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 19 years to 42 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Giza, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.